{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:21:18Z","timestamp":1780417278774,"version":"3.54.1"},"reference-count":20,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1248\/bpb.b17-00605","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T22:22:17Z","timestamp":1522534937000},"page":"644-648","source":"Crossref","is-referenced-by-count":20,"title":["Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan"],"prefix":"10.1248","volume":"41","author":[{"given":"Hiroaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kontani","sequence":"additional","affiliation":[{"name":"Department of Respiratory, Breast and Endocrine Surgery, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Motoki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kosaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Yokomise","sequence":"additional","affiliation":[{"name":"Department of Respiratory, Breast and Endocrine Surgery, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Houchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kagawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) AVASTIN package insert, Chugai Pharmacy, Tokyo, Japan (May 2016)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sane DC, Anton L, Brosnihan KB. Angiogenetic growth factors and hypertension. Angiogenesis<\/i>, 7<\/b>, 193\u2013201 (2004).","DOI":"10.1007\/s10456-004-2699-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin. Drug Saf.<\/i>, 5<\/b>, 553\u2013566 (2006).","DOI":"10.1517\/14740338.5.4.553"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaqqin SE. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med.<\/i>, 358<\/b>, 1129\u20131136 (2008).","DOI":"10.1056\/NEJMoa0707330"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus<\/i> paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.<\/i>, 357<\/b>, 2666\u20132676 (2007).","DOI":"10.1056\/NEJMoa072113"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Miles DW, Chan A, Dirix LY, Cort\u00e9s J, Pivot X, Tomczak P, Delozier T, Shon JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol.<\/i>, 28<\/b>, 3239\u20133247 (2010).","DOI":"10.1200\/JCO.2008.21.6457"},{"key":"7","unstructured":"7) Robert NJ, Di\u00e9ras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O\u2019Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol.<\/i>, 29<\/b>, 1252\u20131260 (2011)."},{"key":"8","unstructured":"8) Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M. bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J. Oncol.<\/i>, 2012<\/b>, 417673 (2012)."},{"key":"9","unstructured":"9) Aogi K, Masuda N, Ohno S, Oda T, Iwata H, Kashiwaba M, Fujiwara Y, Kamigaki S, Ito Y, Ueno T, Takashima S. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res. Treat.<\/i>, 129<\/b>, 829\u2013838 (2011)."},{"key":"10","unstructured":"10) Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O\u2019Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol.<\/i>, 29<\/b>, 4286\u20134293 (2011)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.<\/i>, 23<\/b>, 792\u2013799 (2005).","DOI":"10.1200\/JCO.2005.05.098"},{"key":"12","unstructured":"12) Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer. J. Clin. Oncol.<\/i>, 31<\/b>, 1719\u20131725 (2013)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczac P, Provencher L, Cort\u00e9s J, Delmar PR, Scherer SJ. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br. J. Cancer<\/i>, 108<\/b>, 1052\u20131060 (2013).","DOI":"10.1038\/bjc.2013.69"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol.<\/i>, 20<\/b>, 227\u2013230 (2009).","DOI":"10.1093\/annonc\/mdn637"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Horinouchi Y, Sakurada T, Nakamura T, Tajima S, Nishisako H, Abe S, Teraoka K, Kujime T, Kawazoe K, Minakuchi K. Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer. Yakugaku Zasshi<\/i>, 131<\/b>, 1251\u20131257 (2011).","DOI":"10.1248\/yakushi.131.1251"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. J. Clin. Cancer Res.<\/i>, 13<\/b>, 3913\u20133921 (2007).","DOI":"10.1158\/1078-0432.CCR-06-2610"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.<\/i>, 22<\/b>, 1201\u20131208 (2004).","DOI":"10.1200\/JCO.2004.10.182"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santro A, Bets D, Muesser M, Harstric A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.<\/i>, 351<\/b>, 337\u2013345 (2004).","DOI":"10.1056\/NEJMoa033025"},{"key":"19","unstructured":"19) Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol.<\/i>, 26<\/b>, 4672\u20134678 (2008)."},{"key":"20","unstructured":"20) Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist<\/i>, 18<\/b>, 273\u2013280 (2013)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/4\/41_b17-00605\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T21:11:27Z","timestamp":1571001087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/4\/41_b17-00605\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00605","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}